Marshall Urist sells shares at Royalty Pharma plc (NASDAQ: RPRX)

Rhea-AI Filing Summary

Royalty Pharma plc (RPRX) reported reported Form 144 activity showing insider transactions by Marshall Urist. The filing lists sales of 13,684 shares on 05/14/2026 for $726,137.82 and 13,684 shares on 05/20/2026 for $721,837.21. The excerpt also shows a 9,098-share Equity Performance Award granted on 05/08/2026.

Insights

Insider Transactions Analyst

Two near-term sales by Marshall Urist; award grant also disclosed.

The excerpt lists two dispositions of 13,684 shares each on 05/14/2026 and 05/20/2026, with cash amounts shown. It also records an Equity Performance Award of 9,098 shares granted on 05/08/2026.

These entries document reported transactions; cash‑flow treatment and whether sales were pursuant to a trading plan are not stated in the provided excerpt. Subsequent filings may clarify holdings and rationale.

Key Figures

Sale 1: 13,684 shares Sale 2: 13,684 shares Equity Performance Award: 9,098 shares +2 more

5 metrics

Sale 1 13,684 shares sold on 05/14/2026 for $726,137.82

Sale 2 13,684 shares sold on 05/20/2026 for $721,837.21

Equity Performance Award 9,098 shares granted on 05/08/2026 as equity compensation

Proceeds (Sale 1) $726,137.82 gross amount shown for 05/14/2026 sale

Proceeds (Sale 2) $721,837.21 gross amount shown for 05/20/2026 sale

Key Terms

Form 144, Equity Performance Award, Class A Ordinary Shares

3 terms

Form 144 regulatory

"144: Securities Sold During The Past 3 Months"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Equity Performance Award financial

"Granted as part of issuer equity compensation program"

Class A Ordinary Shares financial

"Class A Ordinary Shares | 05/08/2026"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

FAQ

What did Royalty Pharma (RPRX) report in this Form 144?

The filing shows insider Marshall Urist sold 13,684 shares on 05/14/2026 for $726,137.82 and sold 13,684 shares on 05/20/2026 for $721,837.21. It also notes a 9,098-share award granted on 05/08/2026.

Who is the reporting person for the transactions in RPRX Form 144?

The excerpt identifies Marshall Urist as the reporting person associated with the two sales dated 05/14/2026 and 05/20/2026. The filing lists addresses tied to the reporting person but does not elaborate further on ownership structure in this excerpt.

How many shares were granted under the Equity Performance Award?

The excerpt records an Equity Performance Award of 9,098 shares of Class A Ordinary Shares granted on 05/08/2026. The filing states it was granted as part of the issuer's equity compensation program.

Do these Form 144 entries state whether proceeds go to the issuer?

The provided excerpt does not specify proceeds treatment. The two sale lines list gross proceeds for the reporting person but do not state whether the company receives any proceeds or whether sales were secondary dispositions or issuer-related.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 06/24/2026 - 04:15 PM Accepted by SEC EDGAR 06/24/2026 - 04:14 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	9098	502066.55	443274104	06/24/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Shares	05/08/2026	Equity Performance Award	Royalty Pharma plc			9098	05/08/2026	Granted as part of issuer equity compensation program

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Marshall Urist 110 EAST 59TH STREET New York NY 10022	Common Stock	05/14/2026	13684	726137.82
Marshall Urist 110 EAST 59TH STREET New York NY 10022	Common Stock	05/20/2026	13684	721837.21

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)